#LCSM Transcript

Healthcare social media transcript of the #LCSM hashtag.
().
See #LCSM Influencers/Analytics.

Sign up for FREE Symplur Account and Get
  • Create Transcripts with Custom Dates
  • Get Custom Influencer Lists
  • 3x Hashtag Search Results
Sign Up Now
ProfileTweet
Brendon Stiles @BrendonStilesMD
Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: Hi everyone. Starting soon. Please join #lcsm community and @lcsmchat to discuss #wclc19 from @iaslc! Starting in j…
Jean Parks @geekbabe
RT @BrendonStilesMD: Hi everyone. Starting soon. Please join #lcsm community and @lcsmchat to discuss #wclc19 from @iaslc! Starting in j…
Jill @jillfeldman4
Hi it's Jill from Chicago. Looking forward to your recap of #WCLC19 @BrendonStilesMD #LCSM
Jean Parks @geekbabe
RT @BrendonStilesMD: Welcome everyone! You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Brendon Stiles @BrendonStilesMD
To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twi…
Brendon Stiles @BrendonStilesMD
More info at https://t.co/Lx9qF406C9 #lcsm
Bob Steele @steele_bob
Good evening folks. Bob here in Greensboro, NC. Looking 4ward to hearing the news from Spain. #lcsm
Brendon Stiles @BrendonStilesMD
@jillfeldman4 Looking forward to hearing your thoughts! #lcsm
Janet Freeman-Daily @JFreemanDaily
Good evening all! Janet Freeman-Daily in Seattle. Looking forward to tonight's chat about #WCLC19 wrap-up! #LCSM
Brendon Stiles @BrendonStilesMD
@GinaHollenbeck Hi Gina! #lcsm
Lung Cancer Research Foundation @lcrf_org
Excited about tonight’s #LCSM chat and catching up after this year's #wclc2019 with @BrendonStilesMD. Join us!
Faces of Lung Cancer @LungCancerFaces
Deana here in muggy Los Angeles. I’ll be tweeting from the @lcsmchat account tonight. #lcsm
Jean Parks @geekbabe
Hi everyone stage IV almost 5 yrs, treated at @MGHCancerCenter #LCSM
Brendon Stiles @BrendonStilesMD
We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm
Tim Kruser @TimothyKruserMD
Tim Kruser here. Looking forward to learning as had to miss WCLC19 given it was back-to-back with #ASTRO19 :( #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm
Brendon Stiles @BrendonStilesMD
@TimothyKruserMD Always love your input! #lcsm
#LCSM Chat @lcsmchat
@steele_bob Evening, Bob! #lcsm
Lung Cancer Sux @LungCancerSux
@BrendonStilesMD @jillfeldman4 Hi! Glorianne in CT signing on! Great topic! #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: More info at https://t.co/Lx9qF406C9 #lcsm
Peggy Dennis @peggyddennis
Peggy Dennis joining from Denver. Looking forward to the update. #lcsm
Brendon Stiles @BrendonStilesMD
I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and @IASLC member. #lcsm
Brendon Stiles @BrendonStilesMD
I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife works for @ppdCRO. These don’t affect opinions expressed tonight. #lcsm
Jill Hamer-Wilson 🇨🇦 @JillHW
Hi It's Jill from Ottawa Canada, looking forward to my first #LCSM chat, and the recap of #WCLC19 and #STARS19
Jean Parks @geekbabe
RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and @IASLC member. #lcsm
Brendon Stiles @BrendonStilesMD
@LungCancerSux @jillfeldman4 So glad you are here! #lcsm
Janet Freeman-Daily @JFreemanDaily
@GinaHollenbeck @BrendonStilesMD Hi Gina! Remember to include #LCSM in all your tweets so they'll appear in the Chat.
#LCSM Chat @lcsmchat
@LungCancerSux @BrendonStilesMD @jillfeldman4 Hi Jill and Glorianne! #lcsm
KC Dill @kasedill
Hello from Houston, we are high and dry in the suburbs, lots of rain here.. #LCSM
Brendon Stiles @BrendonStilesMD
@JillHW Hi Jill. A true STAR! #lcsm
Jean Parks @geekbabe
RT @JFreemanDaily: Good evening all! Janet Freeman-Daily in Seattle. Looking forward to tonight's chat about #WCLC19 wrap-up! #LCSM
Henning Willers, MD @HenningWillers
Hi all, @henningwillers here, also fresh back from ASTRO19 but wasn't at World Lung #lcsm
Gina Hollenbeck @GinaHollenbeck
Hi! Gina here. Stage IV, ALK Positive- President of ALK Positivw a Patient lead group of 1800+ patients and caregivers #lcsm
Brendon Stiles @BrendonStilesMD
In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV
Jean Parks @geekbabe
RT @BrendonStilesMD: I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife works for…
#LCSM Chat @lcsmchat
@BrendonStilesMD @GinaHollenbeck Welcome, Gina! Remember to include #lcsm in all your tweets.
Deb Smith 🦋🌻🦉🐢🌿 @debsmithbeach
Deb here, from NH. 8 yrs post dx, on Tagrisso almost 6 yrs, EGFR/T790. #lcsm
#LCSM Chat @lcsmchat
@geekbabe @MGHCancerCenter Hey, Jean! #lcsm
Brendon Stiles @BrendonStilesMD
@HenningWillers @HenningWillers Glad you made it! #lcsm Sorry to miss ASTRO!
#LCSM Chat @lcsmchat
@TimothyKruserMD Welcome! #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV
#LCSM Chat @lcsmchat
@peggyddennis Hi Peggy! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and @IASLC member. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I would like to disclose conflicts – I chair @lcrf_org & have worked with @astrazeneca & @medtronic. My wife works for…
#LCSM Chat @lcsmchat
@JillHW Hey Jill! #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @TimothyKruserMD: Cool work from @WashURadOnc w/ their friendly #tssmn colleagues. Developed algorithm to "assign" surgery vs SBRT. Amon…
Brendon Stiles @BrendonStilesMD
#WCLC19 is a showcase for all of the latest news and advances in lung cancer #lcsm
#LCSM Chat @lcsmchat
@kasedill Welcome! #lcsm
Gina @EAustin1969
Gina and I’m actually here. Can’t wait to hear all the new stuff #LCSM
Brendon Stiles @BrendonStilesMD
We will get started soon. First, a few reminders… #lcsm
#LCSM Chat @lcsmchat
@HenningWillers Welcome! #lcsm
Brendon Stiles @BrendonStilesMD
Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm
#LCSM Chat @lcsmchat
@GinaHollenbeck Hey Gina! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV
Brendon Stiles @BrendonStilesMD
If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. #lcsm
#LCSM Chat @lcsmchat
@debsmithbeach Hi Deb! #lcsm
Brendon Stiles @BrendonStilesMD
I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm
Charis Stacey @Charis_Stacey
Charis here, from England. I lead Lung health checks programme. #LCSM
Habitility @habitility
#guaidoelparaco, #geekyweather, #gobirds, #infinite, #mugclub, #prichan, #nstemi, #pegged, #losamoresstyle, #6o, #marijuana, #lcsm, #mytcisbetterbecause, #clinicadelgado, #jumatberkah, #wjsn, #veteran, #pintowards, #sisi_out, #bnk48, #choosemaxime, #chanbaek, #kcon2019thailand, \ https://t.co/kbjGZn9WvU
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: #WCLC19 is a showcase for all of the latest news and advances in lung cancer #lcsm
#LCSM Chat @lcsmchat
@EAustin1969 Hello Gina! #lcsm
Brendon Stiles @BrendonStilesMD
We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. Great group already! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm
NCI Cancer Stats @NCICancerStats
The overall trends for new cases and deaths of lung and bronchial cancer have steadily declined since 1995. Learn more about this cancer from our stat fact sheet: https://t.co/BVqvN4e1pm #LCSM https://t.co/qFHrSzI6BL
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience. #lcsm
Brendon Stiles @BrendonStilesMD
@Charis_Stacey Thanks for joining! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol…
Habitility @habitility
Check out my Gig on Fiverr: render a site plan or landscape drawing https://t.co/FSPkI0OfD6 #guaidoelparaco, #geekyweather, #gobirds, #infinite, #mugclub, #prichan, #nstemi, #pegged, #losamoresstyle, #6o, #marijuana, #lcsm, #mytcisbetterbecause, #clinicadelgado, #jumatberkah,
Brendon Stiles @BrendonStilesMD
@EAustin1969 Glad you made it! #lcsm
#LCSM Chat @lcsmchat
@Charis_Stacey Welcome, Charis! #lcsm
Habitility @habitility
Check out my Gig on Fiverr: do architectural drawings or autocad floorplan https://t.co/HCG76yp3IU #guaidoelparaco, #geekyweather, #gobirds, #infinite, #mugclub, #prichan, #nstemi, #pegged, #losamoresstyle, #6o, #marijuana, #lcsm, #mytcisbetterbecause, #clinicadelgado,
Brendon Stiles @BrendonStilesMD
T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. Great…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
Betsy @wildwestannie
Hi, Betsy here, listening intently 😊 #LCSM
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
#LCSM Chat @lcsmchat
@wildwestannie Hi Betsy! #lcsm
Brendon Stiles @BrendonStilesMD
T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm
Brendon Stiles @BrendonStilesMD
T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currently used. https://t.co/vWMM0ySB3y #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm
puterimaya @puterimaya6
https://t.co/vKz0sMg9MI , #geekyweather, #gobirds, #infinite, #mugclub, #prichan, #nstemi, #pegged, #losamoresstyle, #6o, #marijuana, #lcsm, #mytcisbetterbecause, #clinicadelgado, #jumatberkah, #wjsn,
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Brendon Stiles @BrendonStilesMD
T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Janet Freeman-Daily @JFreemanDaily
Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Brendon Stiles @BrendonStilesMD
Never smokers take note! #lcsm
Shelly ET @shelly_et
#lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Jill @jillfeldman4
T1 the presidential symposium featured abstracts on strategies to improve efficiency of screening. The one on blood test to identify tumor markers is huge - fingers crossed! #LCSM
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Ricardo Bruges Maya @BrugesMaya
RT @ChristianRolfo: Our paper is online! Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-…
Timothy Craig Allen @TimAllenMDJD
"...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm
#LCSM Chat @lcsmchat
@shelly_et Hey Shelly! Awesome haircut at #WCLC19 #lcsm
Brendon Stiles @BrendonStilesMD
T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5J #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: Never smokers take note! #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Brendon Stiles @BrendonStilesMD
@shelly_et Hi Shelly! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Never smokers take note! #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM https://t.co…
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
#LCSM Chat @lcsmchat
RT @jillfeldman4: T1 the presidential symposium featured abstracts on strategies to improve efficiency of screening. The one on blood test…
colleen ziegler @ZieglerColleen
#lcsm a few minutes late...Colleen from Rochester joining
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: "...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm https://t.co/B7RsT…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
Janet Freeman-Daily @JFreemanDaily
Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
Brendon Stiles @BrendonStilesMD
T1. This study was also important because it included a high rate of low income patients and demonstrated high adherence rates, even in this high risk group. #lcsm https://t.co/Jud9FF3ULi
Bob Steele @steele_bob
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @JFreemanDaily: Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM https://t.co…
Lillian Leigh @ProjectBreath
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
#LCSM Chat @lcsmchat
@ZieglerColleen Hi Colleen! #lcsm
Timothy Craig Allen @TimAllenMDJD
"...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm
Lillian Leigh @ProjectBreath
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
Shelly ET @shelly_et
Hello! Thanks! I'm thinking about a color for my mohawk... Any suggestions?? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N…
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
Brendon Stiles @BrendonStilesMD
T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to improve detection rates and to guide screening intervals. #lcsm https://t.co/YiqIvDo6FP
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
Bob Steele @steele_bob
RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
Brendon Stiles @BrendonStilesMD
RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp…
Lung Cancer Research Foundation @lcrf_org
Lung cancer screening: such an important topic with so much potential for impact. It is great to see continued progress on this front. #lcsm
Brendon Stiles @BrendonStilesMD
T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
Charis Stacey @Charis_Stacey
Need to develop real world implementation evidence. Uptake and outcome. Smoking cessation a vital component. #LCSM
Janet Freeman-Daily @JFreemanDaily
More from a #WCLC19 plenary about #lungcancer #screening. #lcsm
#LCSM Chat @lcsmchat
I’m partial to purple (Deana) #lcsm
Lillian Leigh @ProjectBreath
RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp…
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
Lillian Leigh @ProjectBreath
RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc
Bob Steele @steele_bob
RT @Charis_Stacey: Need to develop real world implementation evidence. Uptake and outcome. Smoking cessation a vital component. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @IASLC: IASLC Board Member @RamalingamMD presents on disparities in LC, highlighting the importance of #tobaccocontrol, the gaps in edu.…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp…
#LCSM Chat @lcsmchat
RT @lcrf_org: Lung cancer screening: such an important topic with so much potential for impact. It is great to see continued progress on th…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
Bob Steele @steele_bob
RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc
#LCSM Chat @lcsmchat
RT @Charis_Stacey: Need to develop real world implementation evidence. Uptake and outcome. Smoking cessation a vital component. #LCSM
Brendon Stiles @BrendonStilesMD
T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc
Nava Rodrigues, D @daninava
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
Jean Parks @geekbabe
@BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM
Brendon Stiles @BrendonStilesMD
@Charis_Stacey Totally agree. Scottish study went a long way towards this. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
Lillian Leigh @ProjectBreath
RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm
#LCSM Chat @lcsmchat
RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM
Brendon Stiles @BrendonStilesMD
RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM
Bob Steele @steele_bob
RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM
KC Dill @kasedill
RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. The risk calculator uses 7 nonsmoking and 4 smoking predictors to assign a risk score. #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @TimAllenMDJD: "...includes seven antigens. These include p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4." #lcsm https://t.co/n0u7N…
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
Lung Cancer Research Foundation @lcrf_org
RT @geekbabe: @BrendonStilesMD Low income patients need to be included in screenings & good tx in greatly increased numbers #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T1 the presidential symposium featured abstracts on strategies to improve efficiency of screening. The one on blood test…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp…
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @TimAllenMDJD: "...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm https://t.co/B7RsT…
Brendon Stiles @BrendonStilesMD
@HenningWillers That screening need and interval should be defined by individual risks. Suppose not really prevention... #lcsm
Timothy Craig Allen @TimAllenMDJD
Personalized Prevention: the new personalized medicine #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: "...screening with low-dose CT saves lives by reducing lung cancer mortality by at least 20%..." #lcsm https://t.co/B7RsT…
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
Brendon Stiles @BrendonStilesMD
RT @lcrf_org: Lung cancer screening: such an important topic with so much potential for impact. It is great to see continued progress on th…
Bob Steele @steele_bob
RT @TimAllenMDJD: Personalized Prevention: the new personalized medicine #lcsm https://t.co/0OXR2XgHin
Deb Smith 🦋🌻🦉🐢🌿 @debsmithbeach
@BrendonStilesMD I’m glad to see non smokers considered! #LCSM
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @jillfeldman4: T1 the presidential symposium featured abstracts on strategies to improve efficiency of screening. The one on blood test…
Jean Parks @geekbabe
@TimAllenMDJD @BrendonStilesMD P53 would have caught me before I was stage IV #LCSM
Laura Greco @lgreco_ny
Laura here,late. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. A Scottish study showed that a blood test could improve detection of early stage cancer. https://t.co/5nkt7opI5…
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: Never smokers take note! #lcsm
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: T1. Several important presentations, including 3 in Presidential Session on Screening. #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: @HenningWillers That screening need and interval should be defined by individual risks. Suppose not really prevention.…
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: T1. Lung cancer screening was a hot topic at #WCLC19. What is new in that area? #lcsm
KC Dill @kasedill
@lgreco_ny Hi Laura #LCSM
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. Great…
Brendon Stiles @BrendonStilesMD
T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. This study was also important because it included a high rate of low income patients and demonstrated high adhere…
OurWarOnCancer @OurWarOnCancer
RT @BrendonStilesMD: T1. One was focused on expanding screening based upon a risk prediction model, rather than on fixed criteria currentl…
Faces of Lung Cancer @LungCancerFaces
If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there.
Brendon Stiles @BrendonStilesMD
T2 coming soon! #lcsm
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: In this week’s chat we hope to review highlights from #WCLC19 in Barcelona. #lcsm https://t.co/kzNWZg2jVV
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. And the BioMILD trial from Italy also focused on using a blood based test in conjunction with CT screening to imp…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
Brendon Stiles @BrendonStilesMD
RT @LungCancerFaces: If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there.
Tim Kruser @TimothyKruserMD
T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase screening rates! #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
#LCSM Chat @lcsmchat
@lgreco_ny Hey Laura! #lcsm
Brendon Stiles @BrendonStilesMD
T2 will need some oncologists and pathologists! #lcsm
Bob Steele @steele_bob
RT @TimothyKruserMD: T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase scr…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @HenningWillers That screening need and interval should be defined by individual risks. Suppose not really prevention.…
OurWarOnCancer @OurWarOnCancer
RT @JFreemanDaily: Breath testing may be possible for #lungcancer #screening. #LCSM #WCLC19 https://t.co/yCL1bcrOYM
Gina Hollenbeck @GinaHollenbeck
@BrendonStilesMD A mobile unit was on display for screening in rural areas. Wish it wasn’t just for smokers. #WCLC2019, #lcsm https://t.co/4L7TemzWnR
Brendon Stiles @BrendonStilesMD
T2. What is important to know about molecular testing? Is universal testing coming? #lcsm
Charis Stacey @Charis_Stacey
Agree, Nelson paper needed. #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: Hi everyone. Starting soon. Please join #lcsm community and @lcsmchat to discuss #wclc19 from @iaslc! Starting in j…
#LCSM Chat @lcsmchat
RT @LungCancerFaces: If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there.
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. BioMILD investigator suggested that “personalized prevention is possible”! #lcsm
#LCSM Chat @lcsmchat
RT @TimothyKruserMD: T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase scr…
Deb Smith 🦋🌻🦉🐢🌿 @debsmithbeach
@BrendonStilesMD T1: What factors are involved for nonsmokers? I’m curious if I would qualify for screening. #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
Hi- Lecia Sequist, med Onc from MGH here trying to catch a few topics while also at a middle school back to school night. #lcsm
Timothy Craig Allen @TimAllenMDJD
You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm
KC Dill @kasedill
RT @BrendonStilesMD: T2 will need some oncologists and pathologists! #lcsm
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Personalized Prevention: the new personalized medicine #lcsm https://t.co/0OXR2XgHin
Brendon Stiles @BrendonStilesMD
T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcsm https://t.co/qMRwz4DQNl
Bob Steele @steele_bob
RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @JFreemanDaily: More from a #WCLC19 plenary about #lungcancer #screening. #lcsm https://t.co/OWLX2klquc
Brendon Stiles @BrendonStilesMD
RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. Hopefully NELSON results will be published soon and we can break through on screening - still underutilized. #lcsm
Lung Cancer Sux @LungCancerSux
RT @TimothyKruserMD: T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase scr…
Katsuaki Maehara Ph.D. 🇯🇵 @KatsuakiMaehara
RT @BrendonStilesMD: T1. BioMILD article: https://t.co/pC68BLO6B8 #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @LungCancerFaces: If you’re just watching, please send a blank tweet with the hashtag #lcsm so we know you’re out there.
Katie Brown @brownbeansprout
RT @BrendonStilesMD: T2. What is important to know about molecular testing? Is universal testing coming? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimothyKruserMD: T1. Hope efforts at better accuracy can erode (good faith) opposition from those like @VPrasadMDMPH--need increase scr…
Brendon Stiles @BrendonStilesMD
@LeciaSequist Always amazing! Thanks for joining! #lcsm
Timothy Craig Allen @TimAllenMDJD
NGS FTW #lcsm
Bill Brady @sharemyopinion
@LungCancerFaces #lcsm
Lung Cancer Research Foundation @lcrf_org
One step closer to the ever elusive "liquid biopsy": RT @BrendonStilesMD: T1. BioMILD article: https://t.co/XlZOf2hhUm #lcsm
Brendon Stiles @BrendonStilesMD
T2. There is remarkable variability in what individual institutions test for. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @GinaHollenbeck: @BrendonStilesMD A mobile unit was on display for screening in rural areas. Wish it wasn’t just for smokers. #WCLC2019,…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. What is important to know about molecular testing? Is universal testing coming? #lcsm
Faces of Lung Cancer @LungCancerFaces
@TimothyKruserMD @VPrasadMDMPH You’re a Doc after my own heart, Tim. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Matthew Smeltzer presented results from @iaslc survey: https://t.co/roNRDeCfkG #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: Hi- Lecia Sequist, med Onc from MGH here trying to catch a few topics while also at a middle school back to school night.…
Janet Freeman-Daily @JFreemanDaily
@LeciaSequist Welcome Lecia! #LCSM
Brendon Stiles @BrendonStilesMD
T2. Top five barriers: cost, quality, access, awareness, and time. We have to break these down systematically. Lives depend upon it. #lcsm
Timothy Craig Allen @TimAllenMDJD
Back atcha @LungCancerFaces #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcs
Bob Steele @steele_bob
RT @BrendonStilesMD: T2. There is remarkable variability in what individual institutions test for. #lcsm
Dr Chandan K Das @ckdasoncology
RT @KadrinWilfong: @PeerView Live at #ASTRO19: Dr. Kathryn Beal, @PatelOncology , and @BrainTumorDoc share an algorithm for management of n…
Ehsan H. Balagamwala @DrEHBalagamwala
RT @JAMAOnc: Rand ph2 trial of pembro vs stereotactic body radiation therapy (SBRT) to a lesion before pembro for adv NSCLC shows doubling…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2 will need some oncologists and pathologists! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcs
Brendon Stiles @BrendonStilesMD
T2. Currently, too many stage IV patients are not tested or have therapy started prior to testing results coming back – especially in developing countries. #lcsm
#LCSM Chat @lcsmchat
RT @GinaHollenbeck: @BrendonStilesMD A mobile unit was on display for screening in rural areas. Wish it wasn’t just for smokers. #WCLC2019,…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. What is important to know about molecular testing? Is universal testing coming? #lcsm
Laura Greco @lgreco_ny
@kasedill @lgreco_ny #lcsm
#LCSM Chat @lcsmchat
@LeciaSequist Welcome! #lcsm
Timothy Craig Allen @TimAllenMDJD
Need evidence-based standardization. #lcsm
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD @DCarboneMD @ChristianRolfo That session went by REALLY fast. I'll have to rewatch it a few times to absorb everything. #LCSM
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Great session on testing for molecular markers at #WCLC19 including talks by @DCarboneMD and @ChristianRolfo #lcs
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: NGS FTW #lcsm https://t.co/QewB9ywD45
Brendon Stiles @BrendonStilesMD
T2. Older study, but problem still pervasive. #lcsm https://t.co/dSO0BgjaH3
#LCSM Chat @lcsmchat
@sharemyopinion @LungCancerFaces Welcome, Bill. #lcsm
#LCSM Chat @lcsmchat
RT @lcrf_org: One step closer to the ever elusive "liquid biopsy": RT @BrendonStilesMD: T1. BioMILD article: https://t.co/XlZOf2hhUm #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. There is remarkable variability in what individual institutions test for. #lcsm
Shelly ET @shelly_et
I'm glad to see it is not in the shape of a cigarette. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Not testing can sometimes lead to ineffective or even counterproductive treatments. #lcsm
Bob Steele @steele_bob
RT @TimAllenMDJD: Need evidence-based standardization. #lcsm https://t.co/tygTMns5jj
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Matthew Smeltzer presented results from @iaslc survey: https://t.co/roNRDeCfkG #lcsm
Betsy @wildwestannie
RT @TimAllenMDJD: You won't find what you don't look for. Early diagnosis provides the best chance for cure. #lcsm https://t.co/WSMN3IK6TU
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Top five barriers: cost, quality, access, awareness, and time. We have to break these down systematically. Liv…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Currently, too many stage IV patients are not tested or have therapy started prior to testing results coming back…
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Need evidence-based standardization. #lcsm https://t.co/tygTMns5jj
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Older study, but problem still pervasive. #lcsm https://t.co/dSO0BgjaH3
Brendon Stiles @BrendonStilesMD
T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
#LCSM Chat @lcsmchat
RT @shelly_et: I'm glad to see it is not in the shape of a cigarette. #lcsm https://t.co/MVYdlmFbR3
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Not testing can sometimes lead to ineffective or even counterproductive treatments. #lcsm
Timothy Craig Allen @TimAllenMDJD
Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV
Brendon Stiles @BrendonStilesMD
T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
Bob Steele @steele_bob
RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https…
Lung Cancer Sux @LungCancerSux
RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https…
Bob Steele @steele_bob
RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for certain biomarkers than others. No one test is perfect for all. Might be good to perform both liquid biopsy and tissue biopsy if possible. #LCSM
Brendon Stiles @BrendonStilesMD
T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @ChristianRolfo #lcsm https://t.co/PAlpXCfgqR
Timothy Craig Allen @TimAllenMDJD
#StandardOfCare #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @lcrf_org: One step closer to the ever elusive "liquid biopsy": RT @BrendonStilesMD: T1. BioMILD article: https://t.co/XlZOf2hhUm #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T2. Older study, but problem still pervasive. #lcsm https://t.co/dSO0BgjaH3
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. There is remarkable variability in what individual institutions test for. #lcsm
Faces of Lung Cancer @LungCancerFaces
Welcome, Sue! Glad you’re here. If you want to tweet during the chat, remember to include the hashtag #lcsm.
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Brendon Stiles @BrendonStilesMD
RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Matthew Smeltzer presented results from @iaslc survey: https://t.co/roNRDeCfkG #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @Christi
Laura Greco @lgreco_ny
RT @BrendonStilesMD: T2. Not testing can sometimes lead to ineffective or even counterproductive treatments. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Great point by @DCarboneMD that the cost of molecular testing is often less than that of a single PET scan – and often much more impactful! #lcsm https://t.co/iwIlXbgvaf
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Top five barriers: cost, quality, access, awareness, and time. We have to break these down systematically. Liv…
Jean Parks @geekbabe
RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Currently, too many stage IV patients are not tested or have therapy started prior to testing results coming back…
Faces of Lung Cancer @LungCancerFaces
#lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Need evidence-based standardization. #lcsm https://t.co/tygTMns5jj
Deb Smith 🦋🌻🦉🐢🌿 @debsmithbeach
RT @JFreemanDaily: @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for cer…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Older study, but problem still pervasive. #lcsm https://t.co/dSO0BgjaH3
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Not testing can sometimes lead to ineffective or even counterproductive treatments. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. We now have MANY tools to determine molecular drivers of lung cancer – both blood and tissue based. #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https…
Brendon Stiles @BrendonStilesMD
And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Chris Martin @CMPR
#lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for cer…
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Lot of work still to do to provide appropriate and timely lung cancer biomarker testing in the US too. #lcsm #CBCIV https…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @Christi
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Sometimes, blood is all we can get. Great study by @CharuAggarwalMD. #lcsm https://t.co/sfnKvi9bkQ
Brendon Stiles @BrendonStilesMD
T3 on way! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Great point by @DCarboneMD that the cost of molecular testing is often less than that of a single PET scan – and…
#LCSM Chat @lcsmchat
RT @LungCancerFaces: #lcsm https://t.co/cmH4zKXlNr
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. In my opinion, it is critical to test all stage IV tumors. Here are good guidelines from @JTOonline and @Christi
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X
Jan Marie Eberth @jmeberth
Hi #lcsm crew! Hated to miss @IASLC meeting and was hoping to hear @BrendonStilesMD’s take on the best of the best! Nice to see you all...
Timothy Craig Allen @TimAllenMDJD
And yet payment for biomarker testing remains problematic! Patients usually don't know this. #lcsm #CBCIV
#LCSM Chat @lcsmchat
@CMPR Welcome, Chris! #lcsm
Brendon Stiles @BrendonStilesMD
T3. What was new at #WCLC19 regarding immunotherapy? #lcsm
KC Dill @kasedill
RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Great point by @DCarboneMD that the cost of molecular testing is often less than that of a single PET scan – and…
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X
Brendon Stiles @BrendonStilesMD
@jmeberth @IASLC HELLO! Hope all is well! #lcsm
#LCSM Chat @lcsmchat
@jmeberth @IASLC @BrendonStilesMD Thanks for joining! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: And liquid biopsy is already here to stay! #lcsm https://t.co/YG8NJSck2X
tauromaquiaficionado @taurinaficion
RT @IASLC: Join Latin America’s largest gathering of clinicians, researchers and scientists in the field of #LungCancer and thoracic oncolo…
Dave Bjork @bjork5
@BrendonStilesMD Just joining...sorry I’m late! Dave here from Boston 😊 #LCSM
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: And yet payment for biomarker testing remains problematic! Patients usually don't know this. #lcsm #CBCIV https://t.co/Hz…
Drew Moghanaki @DrewMoghanaki
RT @JFreemanDaily: Lots of plenary presentations about #lungcancer #screening at #WCLC19. Here's one take home message. #LCSM https://t.co…
Jean Parks @geekbabe
What’s sad is small hospitals who don’t do much molecular testing #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. What was new at #WCLC19 regarding immunotherapy? #lcsm
Timothy Craig Allen @TimAllenMDJD
Still very complicated. #lcsm
Jose F. Corona-Cruz @drcoronacruz
#LCSM Late! But wanting to join the conversation José from Mexico City
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. What was new at #WCLC19 regarding immunotherapy? #lcsm
KC Dill @kasedill
RT @TimAllenMDJD: And yet payment for biomarker testing remains problematic! Patients usually don't know this. #lcsm #CBCIV https://t.co/Hz…
Brendon Stiles @BrendonStilesMD
T3. There were several important immunotherapy presentations at #WCLC19 #lcsm
Enlightening Results @GraceCordovano
RT @JFreemanDaily: @BrendonStilesMD My take away from that session: there are many types of biomarker testing, and some work better for cer…
#LCSM Chat @lcsmchat
@bjork5 @BrendonStilesMD Hey, Dave! You’ve been a busy guy. #lcsm
Brendon Stiles @BrendonStilesMD
@bjork5 Will take you any time! Thanks for joining! #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T3. There were several important immunotherapy presentations at #WCLC19 #lcsm
#LCSM Chat @lcsmchat
RT @geekbabe: What’s sad is small hospitals who don’t do much molecular testing #LCSM https://t.co/BRBrJLm5up
Brendon Stiles @BrendonStilesMD
@drcoronacruz Thanks for joining! #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Still very complicated. #lcsm https://t.co/vkbjYwOpgp
Brendon Stiles @BrendonStilesMD
T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very challenging cancer to treat. #lcsm
#LCSM Chat @lcsmchat
@drcoronacruz Hola! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Still very complicated. #lcsm https://t.co/vkbjYwOpgp
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. There were several important immunotherapy presentations at #WCLC19 #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T3. There were several important immunotherapy presentations at #WCLC19 #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. There were several important immunotherapy presentations at #WCLC19 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha…
Dave Bjork @bjork5
@lcsmchat @BrendonStilesMD Ha! We’re all out there... in this together! #lcsm #clinicaltrials
Jean Parks @geekbabe
RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha…
Brendon Stiles @BrendonStilesMD
T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/bYfP0OnJ0K
Brendon Stiles @BrendonStilesMD
T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
Jan Marie Eberth @jmeberth
@BrendonStilesMD Also, lots of variability in timeliness and quality of treatments applied. There should be better incentives to get folks tested and treated based on evidence based guidelines. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
#LCSM Chat @lcsmchat
RT @jmeberth: @BrendonStilesMD Also, lots of variability in timeliness and quality of treatments applied. There should be better incentives…
Brendon Stiles @BrendonStilesMD
T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm
Brendon Stiles @BrendonStilesMD
T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effect in major study presented at #WCLC19 https://t.co/VmgMmGX7N6 #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm
Brendon Stiles @BrendonStilesMD
#lcsm
#LCSM Chat @lcsmchat
@CMPR We 💖 IASLC. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/…
Timothy Craig Allen @TimAllenMDJD
Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T3. Another drug – durvalumab – showed improved survival in patients with small cell cancer. This remains a very cha…
Brendon Stiles @BrendonStilesMD
T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable responses. https://t.co/f16yTGVQsN #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @jmeberth: @BrendonStilesMD Also, lots of variability in timeliness and quality of treatments applied. There should be better incentives…
Jean Parks @geekbabe
RT @BrendonStilesMD: T3. CASPIAN trial: https://t.co/tuHG1xlJOk #lcsm
Bob Steele @steele_bob
RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm
Brendon Stiles @BrendonStilesMD
@TimAllenMDJD Agree totally. #lcsm
Sewanti Limaye @SewantiLimaye
RT @JAMAOnc: Rand ph2 trial of pembro vs stereotactic body radiation therapy (SBRT) to a lesion before pembro for adv NSCLC shows doubling…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm
Shelly ET @shelly_et
@geekbabe @lcsmchat Or the wrong kind of testing. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec…
Lizzie Barclay @LizzieBarclay1
@BrendonStilesMD T1. Attended #WCLC19 - great to see so much focus on lung cancer screening, including optimising patient uptake. Would like to see more discussion on optimising resources to achieve sustainable screening programs. NHS radiology departments already under strain. #LCSM
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst
KC Dill @kasedill
RT @BrendonStilesMD: T3. We are starting to sort out better predictors of who will respond to immunotherapy. https://t.co/OMb1amPyD7 #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec…
Timothy Craig Allen @TimAllenMDJD
#Hope #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable respon…
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst
Dave Bjork @bjork5
#PrecisionMedicine #LCSM
#LCSM Chat @lcsmchat
RT @LizzieBarclay1: @BrendonStilesMD T1. Attended #WCLC19 - great to see so much focus on lung cancer screening, including optimising patie…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable respon…
Jose F. Corona-Cruz @drcoronacruz
A todos los interesados en discutir lo más relevante del #WCLC19, sigan el chat con el hashtag #LCSM ahora mismo se está poniendo muy interesante
Brendon Stiles @BrendonStilesMD
T3. In NADIM with preop immunotherapy, 83% major path response. 91% survival at 18 months in this high risk stage III group! If holds will be new standard of care for IIIA. #lcsm
Jean Parks @geekbabe
RT @LeciaSequist: Hi- Lecia Sequist, med Onc from MGH here trying to catch a few topics while also at a middle school back to school night.…
Timothy Craig Allen @TimAllenMDJD
Jury's still out on TMB. #lcsm
Tim Kruser @TimothyKruserMD
T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAlexLouie #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @TimothyKruserMD: T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAl
Brendon Stiles @BrendonStilesMD
T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over 4x with chemo. Is cure possible? https://t.co/85aIzpvHFI #lcsm
Lung Cancer Sux @LungCancerSux
RT @BrendonStilesMD: T3. Immunotherapy also continues to move into the treatment plan for earlier stage patients w/ some remarkable respon…
Janet Freeman-Daily @JFreemanDaily
RT @drcoronacruz: A todos los interesados en discutir lo más relevante del #WCLC19, sigan el chat con el hashtag #LCSM ahora mismo se está…
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T3. However, story not clear. Tumor mutation burden has been suggested as a good marker, but had no predictive effec…
Brendon Stiles @BrendonStilesMD
@TimAllenMDJD What do you think Tim? #lcsm
TranslationalGenomic @TGEGatONJCRI
RT @UmbertoMalapel1: @ChristianRolfo on Liquid Biopsy @IASLC @OncoAlert @isliquidbiopsy https://t.co/KAH4bpElKf
Henning Willers, MD @HenningWillers
T3 what about neoadjuvant IO + chemo? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. In NADIM with preop immunotherapy, 83% major path response. 91% survival at 18 months in this high risk stage II…
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Jury's still out on TMB. #lcsm https://t.co/fRlldZm2s2
Biniam Kidane @biniamkidaneMD
@LizzieBarclay1 @BrendonStilesMD I wish I could’ve been there. Interested to see experiences in this exact issue across different healthcare systems. #lcsm
Timothy Craig Allen @TimAllenMDJD
Solid. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimothyKruserMD: T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAl
Stephen V Liu @StephenVLiu
T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR #NSCLC identified and 36% never received an EGFR TKI. Survival 21 months with TKI vs 13.3 without. #LCSM https://t.co/zJeL9UtpYe
#LCSM Chat @lcsmchat
RT @drcoronacruz: A todos los interesados en discutir lo más relevante del #WCLC19, sigan el chat con el hashtag #LCSM ahora mismo se está…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over…
TranslationalGenomic @TGEGatONJCRI
RT @IASLC: Liquid biopsy has recently generated great interest as a minimally invasive diagnostic assay to overcome the challenges of tissu…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. In NADIM with preop immunotherapy, 83% major path response. 91% survival at 18 months in this high risk stage II…
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Jury's still out on TMB. #lcsm https://t.co/fRlldZm2s2
Timothy Craig Allen @TimAllenMDJD
All kinds of combinations are being studied. It's exploded! #lcsm
#LCSM Chat @lcsmchat
RT @TimothyKruserMD: T3. Some questions remain still in ES-SCLC despite Caspian and IM-133 data--but stepping in the right direction. @DrAl
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over…
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Solid. #lcsm https://t.co/Lp1BzSRoH1
#LCSM Chat @lcsmchat
RT @HenningWillers: T3 what about neoadjuvant IO + chemo? #lcsm
Brendon Stiles @BrendonStilesMD
@HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose SBRT over chemo any day! Our trial with Durva + 8Gy x 3 was presented at #WCLC19. Encouraging results. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: All kinds of combinations are being studied. It's exploded! #lcsm https://t.co/mteduvc17y
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Solid. #lcsm https://t.co/Lp1BzSRoH1
#LCSM Chat @lcsmchat
RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: All kinds of combinations are being studied. It's exploded! #lcsm https://t.co/mteduvc17y
Laura Greco @lgreco_ny
@HenningWillers It's so interesting... is maybe sequencing everything? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Brendon Stiles @BrendonStilesMD
@TimAllenMDJD Some say it is getting ahead of itself. But I think it is a critical area for stage II/III in particular. Neoadjuvant IO makes much more sense to me than adjuvant! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
KC Dill @kasedill
T3 Nivolumab was a game changer for me! #LCSM
Jose F. Corona-Cruz @drcoronacruz
El screening en Cáncer de Pulmón salva vidas, el estrato socio económico no parece ser una barrera para su implementación y apego #LCSM
Tim Kruser @TimothyKruserMD
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Brendon Stiles @BrendonStilesMD
T4 just around the corner - new targets! #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD T3 we are with you 👍 #radonc #Sabr #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @TimAllenMDJD Some say it is getting ahead of itself. But I think it is a critical area for stage II/III in particula…
Jose Pacheco @LungCancerDr
RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR
Lung Cancer Research Foundation @lcrf_org
@TimAllenMDJD So much work to be done on sorting out the combinations and sequencing of therapy! #lcsm
Timothy Craig Allen @TimAllenMDJD
It may play a useful role when assessed along with other molecular biomarkers. Speculation though. #lcsm #CBCIV
Jean Parks @geekbabe
RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over…
Brendon Stiles @BrendonStilesMD
@lgreco_ny @HenningWillers I do think sequencing will come to be important for almost everything in lung cancer! #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: @TimAllenMDJD Some say it is getting ahead of itself. But I think it is a critical area for stage II/III in particula…
Timothy Craig Allen @TimAllenMDJD
RT @lgreco_ny: @HenningWillers It's so interesting... is maybe sequencing everything? #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Timothy Craig Allen @TimAllenMDJD
RT @StephenVLiu: T2: Testing is not enough - you have to use the targeted therapy! Retrospective RWE Singal et al: 630 patients with #EGFR
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @TimAllenMDJD Some say it is getting ahead of itself. But I think it is a critical area for stage II/III in particula…
Brendon Stiles @BrendonStilesMD
T4. Are there any exciting new targets being investigated in lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @drcoronacruz: El screening en Cáncer de Pulmón salva vidas, el estrato socio económico no parece ser una barrera para su implementación…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @lcrf_org: @TimAllenMDJD So much work to be done on sorting out the combinations and sequencing of therapy! #lcsm
Timothy Craig Allen @TimAllenMDJD
NGS FTW #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: It may play a useful role when assessed along with other molecular biomarkers. Speculation though. #lcsm #CBCIV https://t…
Laura Greco @lgreco_ny
Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonStilesMD @lcrf_org
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @lgreco_ny @HenningWillers I do think sequencing will come to be important for almost everything in lung cancer! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm
KC Dill @kasedill
RT @BrendonStilesMD: T3. We also continue to see encouraging longer term survival from earlier immune trials – 13.4% with nivolumab. Over…
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: NGS FTW #lcsm https://t.co/1hYLgc1wso
Gina @EAustin1969
T3: it’s heartening I see so much progress on treatment options , it’s expanded so much in just 5 years #lcsm
#LCSM Chat @lcsmchat
RT @lgreco_ny: Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonSt
Brendon Stiles @BrendonStilesMD
T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Jose F. Corona-Cruz @drcoronacruz
La biopsia líquida esta más cerca de ser nuestra primera opción al abordar a un paciente con cáncer de pulmón El fin de la era "the tissue is the issue" ? #LCSM
Jean Parks @geekbabe
@BrendonStilesMD Have been on Opdivo for well over 4 yrs, patients with residual cancer need a maintenance tx plan #LCSM
Henning Willers, MD @HenningWillers
RT @lgreco_ny: Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonSt
Brendon Stiles @BrendonStilesMD
@EAustin1969 Without a doubt! #lcsm
#LCSM Chat @lcsmchat
RT @EAustin1969: T3: it’s heartening I see so much progress on treatment options , it’s expanded so much in just 5 years #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Brendon Stiles @BrendonStilesMD
T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-small cell lung cancer. https://t.co/GY6RDUXkmi #lcsm
Dave Bjork @bjork5
#PrecisionMedicine #LCSM
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Brendon Stiles @BrendonStilesMD
LIBRETTO! #lcsm https://t.co/at7CJ8sTGf
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Shelly ET @shelly_et
Ditto!!! #lcsm
Dave Bjork @bjork5
@BrendonStilesMD What about RET? #LCSM
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-s…
Jose F. Corona-Cruz @drcoronacruz
El costo de las pruebas moleculares para seleccionar el mejor tratamiento en Cáncer de Pulmón no es excusa para no realizarlo Aún en países de bajos recursos existe manera de realizarlo gratis para el paciente #LCSM
Jean Parks @geekbabe
RT @BrendonStilesMD: LIBRETTO! #lcsm https://t.co/at7CJ8sTGf
Drew Moghanaki @DrewMoghanaki
Dr. Drew is in finally the house. Just landed in Minneapolis for #AVAHO19 meeting where we are talking about each of these topics as they relate to Veterans with cancer. #lcsm
Brendon Stiles @BrendonStilesMD
T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #lcsm
KC Dill @kasedill
@EAustin1969 This is hope!!! #LCSM
Biniam Kidane @biniamkidaneMD
@BrendonStilesMD T4: many new targets indeed! Having sadly missed #WCLC19, I’m hoping to catch up on what I missed there #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-s…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: LIBRETTO! #lcsm https://t.co/at7CJ8sTGf
Janet Freeman-Daily @JFreemanDaily
RT @drcoronacruz: El screening en Cáncer de Pulmón salva vidas, el estrato socio económico no parece ser una barrera para su implementación…
Jill Hamer-Wilson 🇨🇦 @JillHW
#MoreResearch #MoreSurvivors #ResearchMatters #LCSM
Ricardo González Woge @RicardoWoge
RT @drcoronacruz: La biopsia líquida esta más cerca de ser nuestra primera opción al abordar a un paciente con cáncer de pulmón El fin de…
Brendon Stiles @BrendonStilesMD
@bjork5 #lcsm T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-small cell lung cancer. https://t.co/GY6RDUXkmi
KC Dill @kasedill
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @lcrf_org: @TimAllenMDJD So much work to be done on sorting out the combinations and sequencing of therapy! #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD T4 future may hold biomarker combinations EGFR + Met, KRAS + STK11 et cetera #lcsm
#LCSM Chat @lcsmchat
RT @drcoronacruz: El costo de las pruebas moleculares para seleccionar el mejor tratamiento en Cáncer de Pulmón no es excusa para no realiz…
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: It may play a useful role when assessed along with other molecular biomarkers. Speculation though. #lcsm #CBCIV https://t…
Bob Steele @steele_bob
RT @geekbabe: @BrendonStilesMD Have been on Opdivo for well over 4 yrs, patients with residual cancer need a maintenance tx plan #LCSM
Stephen V Liu @StephenVLiu
T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second line CheckMate studies of nivolumab and 3y follow up from KEYNOTE 024, with first line pembrolizumab (with 3y OS rate of 44%!) #LCSM https://t.co/KhEaOLGhAV
Dave Bjork @bjork5
This!! Support #lungcancer research. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @lgreco_ny @HenningWillers I do think sequencing will come to be important for almost everything in lung cancer! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #…
Brendon Stiles @BrendonStilesMD
T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: @bjork5 #lcsm T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. Are there any exciting new targets being investigated in lung cancer? #lcsm
Lung Cancer Research Foundation @lcrf_org
RT @bjork5: This!! Support #lungcancer research. #lcsm https://t.co/gHJ4aUCNv8
Jean Parks @geekbabe
RT @HenningWillers: @BrendonStilesMD T4 future may hold biomarker combinations EGFR + Met, KRAS + STK11 et cetera #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @bjork5 #lcsm T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion…
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD T4 future may hold biomarker combinations EGFR + Met, KRAS + STK11 et cetera #lcsm
#LCSM Chat @lcsmchat
RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin…
Bob Steele @steele_bob
RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #…
Brendon Stiles @BrendonStilesMD
@HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand interplay. #lcsm
#LCSM Chat @lcsmchat
RT @bjork5: This!! Support #lungcancer research. #lcsm https://t.co/gHJ4aUCNv8
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm
Ken @TheDura01
RT @TimAllenMDJD: Small cell lung cancer is a completely different disease. Neuroendocrine origin. #lcsm https://t.co/TJgUu6fvst
Jose F. Corona-Cruz @drcoronacruz
La inmunoterapia con durvalumab mejoró la supervivencia en Cáncer de Pulmón de Células Pequeñas Mucho camino por recorrer en esta variante histológica, pero el estudio CASPIAN representa un gran avance #LCSM
Jean Parks @geekbabe
RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin…
Henning Willers, MD @HenningWillers
RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin…
Brendon Stiles @BrendonStilesMD
T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlcIWnoT
Timothy Craig Allen @TimAllenMDJD
Lots of research right now about this. #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: @HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand inte…
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlc…
Brendon Stiles @BrendonStilesMD
T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlc…
Bob Steele @steele_bob
RT @TimAllenMDJD: Lots of research right now about this. #lcsm https://t.co/ALAMi84sPz
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm
Dave Bjork @bjork5
@BrendonStilesMD What about BLU667? Promising? #LCSM #clinicaltrials
Narjust Duma, M.D. @NarjustDumaMD
@StephenVLiu @IASLC I agree! #lcsm
Timothy Craig Allen @TimAllenMDJD
Huge. #lcsm #CBCIV
Brendon Stiles @BrendonStilesMD
T4. As mentioned earlier, moving immunotherapy or targeted therapy into earlier stage disease is also hot. #lcsm
Laura Greco @lgreco_ny
IMO the comment of the plenary was whether we really need Phase III trials against chemo where onc drivers@BrendonStilesMD @bjork5 #lcsm
Jean Parks @geekbabe
@StephenVLiu @IASLC 4 yrs & 4 months on Nivo, stage IV, still working #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @lgreco_ny: Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonSt
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm
Narjust Duma, M.D. @NarjustDumaMD
@BrendonStilesMD Together we rise #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @EAustin1969: T3: it’s heartening I see so much progress on treatment options , it’s expanded so much in just 5 years #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. The answer is YES! Always – that is why lung cancer community has to support more research. #lcsm
Brendon Stiles @BrendonStilesMD
T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK, and ROS1. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @drcoronacruz: La biopsia líquida esta más cerca de ser nuestra primera opción al abordar a un paciente con cáncer de pulmón El fin de…
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm
Jill Hamer-Wilson 🇨🇦 @JillHW
#Selpercatinib in patients with #RET fusion positive NSCLC #lungcancer #LCSM #WCLC19 @IASLC @OttawaHospital @OttawaMedOnc
#LCSM Chat @lcsmchat
RT @lgreco_ny: IMO the comment of the plenary was whether we really need Phase III trials against chemo where onc drivers@BrendonStilesMD @…
Brendon Stiles @BrendonStilesMD
@lgreco_ny @bjork5 It is a great question. #lcsm
Pamela Q Fernandes @PamelaQFerns
RT @BrendonStilesMD: T3. Still long way to go for small cell lung cancer. Curves still continue down without plateau. #lcsm https://t.co/…
Jean Parks @geekbabe
RT @BrendonStilesMD: @HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand inte…
Bob Steele @steele_bob
RT @JillHW: #Selpercatinib in patients with #RET fusion positive NSCLC #lungcancer #LCSM #WCLC19 @IASLC @OttawaHospital @OttawaMedOnc https…
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlc…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion positive non-s…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,…
Jose F. Corona-Cruz @drcoronacruz
La inmunoterapia se está moviendo a las etapas no metástasicas del cáncer de pulmón Los esquemas previos a la cirugía prometen mejorar la supervivencia de estos pacientes La respuesta patológica es un buen predictor de que tan efectivo puede ser esta propuesta #LCSM
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm
Brendon Stiles @BrendonStilesMD
@NarjustDumaMD You said it right! Thanks for joining! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: LIBRETTO! #lcsm https://t.co/at7CJ8sTGf
Narjust Duma, M.D. @NarjustDumaMD
@BrendonStilesMD A2: Testing. Testing. Testing. Particularly for our women, never smokers and young patients. #LCSM
Jose F. Corona-Cruz @drcoronacruz
RT @BrendonStilesMD: T3. In NADIM with preop immunotherapy, 83% major path response. 91% survival at 18 months in this high risk stage II…
Janet Freeman-Daily @JFreemanDaily
RT @drcoronacruz: El costo de las pruebas moleculares para seleccionar el mejor tratamiento en Cáncer de Pulmón no es excusa para no realiz…
Jean Parks @geekbabe
RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,…
Tim Kruser @TimothyKruserMD
@lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001, showing even more impressive memory sparing with hippocampal avoidance for those pts where whole brain RT is needed. @NRGonc h/t @SeanSachdevMD for the pics! @BrainTumorInst #lcsm https://t.co/zO5UIMKj76
Jean Parks @geekbabe
RT @JillHW: #Selpercatinib in patients with #RET fusion positive NSCLC #lungcancer #LCSM #WCLC19 @IASLC @OttawaHospital @OttawaMedOnc https…
KC Dill @kasedill
@geekbabe @StephenVLiu @IASLC Amazing! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. RET fusions are only about 2% of NSCLC patients, but great early response to new drug. https://t.co/rkweVlb5bU #…
Brendon Stiles @BrendonStilesMD
Here comes T5! #lcsm
#LCSM Chat @lcsmchat
RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,…
Brendon Stiles @BrendonStilesMD
T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @bjork5 #lcsm T4. LIBRETTO-001 trial showed great results for new drug – Selpercatinib – in patients with RET fusion…
Bob Steele @steele_bob
RT @NarjustDumaMD: @BrendonStilesMD A2: Testing. Testing. Testing. Particularly for our women, never smokers and young patients. #LCSM
Timothy Craig Allen @TimAllenMDJD
Resistance is expected. And highly problematic. Molecular Darwinism. Perhaps to be our greatest cancer molecular therapy challenge. Immunotherapy may ultimately prevail. #lcsm #CBCIV
Jean Parks @geekbabe
RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,…
Janet Freeman-Daily @JFreemanDaily
RT @HenningWillers: @BrendonStilesMD T4 future may hold biomarker combinations EGFR + Met, KRAS + STK11 et cetera #lcsm
Biniam Kidane @biniamkidaneMD
@JillHW @BrendonStilesMD Hi @JillHW ! Hi everyone...just decided to sneak in and learn 😀#lcsm
Jose F. Corona-Cruz @drcoronacruz
El seguimiento a largo plazo de los primeros ensayos con inmunoterapia mostraron una supervivencia nunca antes vista para Cáncer de Pulmón Curación de la enfermedad metástasica? O se convertirá en una enfermedad crónica? #LCSM
KC Dill @kasedill
RT @NarjustDumaMD: @BrendonStilesMD A2: Testing. Testing. Testing. Particularly for our women, never smokers and young patients. #LCSM
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm
Henning Willers, MD @HenningWillers
RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,…
Laura Greco @lgreco_ny
RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,…
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Resistance is expected. And highly problematic. Molecular Darwinism. Perhaps to be our greatest cancer molecular therapy…
Janet Freeman-Daily @JFreemanDaily
RT @bjork5: This!! Support #lungcancer research. #lcsm https://t.co/gHJ4aUCNv8
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. A novel KRAS inhibitor continues to show promising results: https://t.co/JRhCBxWH2D #lcsm
Brendon Stiles @BrendonStilesMD
T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07oQJ5j
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @HenningWillers I think this is key. We have focused so much on single drivers. Just now starting to understand inte…
Shelly ET @shelly_et
Yes, keep them coming! We need more options. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @drcoronacruz: La inmunoterapia con durvalumab mejoró la supervivencia en Cáncer de Pulmón de Células Pequeñas Mucho camino por recorr…
Timothy Craig Allen @TimAllenMDJD
#NoStigma #lcsm
KC Dill @kasedill
RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop https://t.co/EKnlc…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Drew Moghanaki @DrewMoghanaki
RT @BrendonStilesMD: @HenningWillers Certainly NADIM study showing impressive results. However, I personally would take a little low dose…
Jean Parks @geekbabe
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Lots of research right now about this. #lcsm https://t.co/ALAMi84sPz
Brendon Stiles @BrendonStilesMD
T5. Special thanks to @KAdvocate_LCAM and to @BairdAM who really made the program happen. And of course to @iaslc #lcsm
Biniam Kidane @biniamkidaneMD
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. Treatment with new KRAS drug, AMG 510, appeared safe and effective in previously treated patients. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @bjork5: @BrendonStilesMD What about BLU667? Promising? #LCSM #clinicaltrials
Narjust Duma, M.D. @NarjustDumaMD
@lcsmchat Late but here! Happy to connect with all. Narjust Duma Thoracic oncologist at @UWCarbone and @uwsmph #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Huge. #lcsm #CBCIV https://t.co/0aQGKj9VSZ
Ricardo Bruges Maya @BrugesMaya
RT @IASLC: Liquid biopsy has recently generated great interest as a minimally invasive diagnostic assay to overcome the challenges of tissu…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Lung Cancer Research Foundation @lcrf_org
STARS: What an amazing program at this year's #wclc2019 @IASLC #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. As mentioned earlier, moving immunotherapy or targeted therapy into earlier stage disease is also hot. #lcsm
Laura Greco @lgreco_ny
Yes! A lot of posters looking at other mechanisms of growth re ALK. #lcsm @HenningWillers @BrendonStilesMD
Denise Cutlip @dennycee
Sorry to be so late #lcsm
Janet Freeman-Daily @JFreemanDaily
T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advocates (PRAs) & 5 Mentors to #WCLC19 to learn about lung cancer research. Doing it again in 2020 with more PRAs! Learn more here: https://t.co/jHlTI7YGds #LCSM https://t.co/eoqF22fJme
Jill Hamer-Wilson 🇨🇦 @JillHW
Long term IO #hope #LCSM #WCLC19 #lungcancer #immunotherapy @OttawaHospital @OttawaCancer
#LCSM Chat @lcsmchat
Also @JFreemanDaily #lcsm
Brendon Stiles @BrendonStilesMD
T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: Susan McCullough, @kamacintosh, @lgreco_ny, @shelly_et, and @boldcaleb. #lcsm https://t.co/hJVVFM9GQW
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD I missed readouts from adjuvant trials with targeted therapies--were there any at #WCLC19? #LCSM
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo…
Jean Parks @geekbabe
Happy to serve as your human mouse model when needed. Always do blood draws & give extra biopsy samples #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @lgreco_ny: IMO the comment of the plenary was whether we really need Phase III trials against chemo where onc drivers@BrendonStilesMD @…
KC Dill @kasedill
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. We also continue to look for ways to identify and treat resistance to targeted therapies, particularly EGFR, ALK,…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S…
Timothy Craig Allen @TimAllenMDJD
#LikeABoss #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @lgreco_ny @bjork5 It is a great question. #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: T5. Special thanks to @KAdvocate_LCAM and to @BairdAM who really made the program happen. And of course to @iaslc #lc
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Brendon Stiles @BrendonStilesMD
T5. And they had some incredible mentors: @JillHW, @jillfeldman4, @jFreemanDaily, @ProjectBreath, and @dustywater. Thanks @IASLC. #lcsm https://t.co/m25CoQGRG9
Janet Freeman-Daily @JFreemanDaily
RT @drcoronacruz: La inmunoterapia se está moviendo a las etapas no metástasicas del cáncer de pulmón Los esquemas previos a la cirugía p…
Janet Freeman-Daily @JFreemanDaily
T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep should read the #WCLC19 speech delivered by ALK+ NSCLC patient activist and clinical trial Olympian Linnea Olson. #LCSM #clinicaltrials https://t.co/loZAmpfgH3
Laura Greco @lgreco_ny
I can't wait to see what this will be come to be! #stars19 @BrendonStilesMD #lcsm
Jean Parks @geekbabe
RT @NarjustDumaMD: @lcsmchat Late but here! Happy to connect with all. Narjust Duma Thoracic oncologist at @UWCarbone and @uwsmph #LCSM
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo…
Jose F. Corona-Cruz @drcoronacruz
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Jean Parks @geekbabe
RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. And they had some incredible mentors: @JillHW, @jillfeldman4, @jFreemanDaily, @ProjectBreath, and @dustywater.…
Drew Moghanaki @DrewMoghanaki
T5: Can someone explain how radiation oncologists can get involved with STARS? #lcsm
Biniam Kidane @biniamkidaneMD
RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep…
Janet Freeman-Daily @JFreemanDaily
RT @NarjustDumaMD: @BrendonStilesMD A2: Testing. Testing. Testing. Particularly for our women, never smokers and young patients. #LCSM
Jean Parks @geekbabe
RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S…
Dave Bjork @bjork5
Love this. Thanks @JFreemanDaily 🙌 #LCSM #WCLC19
Biniam Kidane @biniamkidaneMD
RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S…
Janet Freeman-Daily @JFreemanDaily
RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,…
Narjust Duma, M.D. @NarjustDumaMD
@BrendonStilesMD @lcsmchat A4: KRAS drugs are promising. It will open many doors for many of our patients. As always, we need more data but recruiting maybe faster than other trials due to frequencies. #LCSM
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: T5. Several patient advocates were invited speakers. Every lung cancer advocate, researcher, clinician, and industry rep…
KC Dill @kasedill
@BrendonStilesMD Loved hearing their updates! #LCSM
Biniam Kidane @biniamkidaneMD
RT @BrendonStilesMD: T5. And they had some incredible mentors: @JillHW, @jillfeldman4, @jFreemanDaily, @ProjectBreath, and @dustywater.…
Brendon Stiles @BrendonStilesMD
Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and remember why we do what we do when patients are there. #lcsm https://t.co/lAAZQD7Yzz
Shelly ET @shelly_et
It is an honor to be involved in this program!! #lcsm
Jean Parks @geekbabe
RT @JFreemanDaily: @BrendonStilesMD I missed readouts from adjuvant trials with targeted therapies--were there any at #WCLC19? #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. What was STARS and how can patients/advocates get more involved at scientific meetings? #lcsm
KC Dill @kasedill
RT @JFreemanDaily: T5. The @IASLC STARS (Supportive Training for Advocates in Research and Science) program brought 5 Patient Research Advo…
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Resistance is expected. And highly problematic. Molecular Darwinism. Perhaps to be our greatest cancer molecular therapy…
Laura Greco @lgreco_ny
RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S…
#LCSM Chat @lcsmchat
RT @NarjustDumaMD: @BrendonStilesMD @lcsmchat A4: KRAS drugs are promising. It will open many doors for many of our patients. As always, we…
Narjust Duma, M.D. @NarjustDumaMD
@HenningWillers @lcsmchat @BrendonStilesMD Promising but hope we are aware of toxicities... and downstream effects #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @drcoronacruz: El seguimiento a largo plazo de los primeros ensayos con inmunoterapia mostraron una supervivencia nunca antes vista para…
Gina Hollenbeck @GinaHollenbeck
@BrendonStilesMD There was a new assay test for ROS1 developed by Ventana. Relatively cheap and you get the results in 2 days. I wish we could have a comprehensive genomic panel assay;) #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. STARS was an amazing program – it brought the patients to the science and to the trials. #lcsm https://t.co/TLv07…
Laura Greco @lgreco_ny
RT @TimothyKruserMD: @lgreco_ny @HenningWillers @BrendonStilesMD @lcrf_org Greatest hits would probably start with the update of NRG-CC001,…
Brendon Stiles @BrendonStilesMD
@DrewMoghanaki Simply admit that surgery is better than SBRT and you are in... Or if easier, volunteer to help! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. Special thanks to @KAdvocate_LCAM and to @BairdAM who really made the program happen. And of course to @iaslc #lc
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb…
Jill @jillfeldman4
T5 So sorry...talking one of my college kids off the ledge. Will have to catch up later, but STARS was amazing thanks to @BairdAM @IASLC @JFreemanDaily @KAdvocate_LCAM Can't wait to see how the program expands. We need more educated research advocates #LCSM
Brendon Stiles @BrendonStilesMD
@JFreemanDaily I didn't see any big ones either. None that I am aware of. #lcsm
Drew Moghanaki @DrewMoghanaki
@shelly_et I want to have this honor too! Where can I sign up? #lcsm @jillfeldman4
Janet Freeman-Daily @JFreemanDaily
RT @lcrf_org: STARS: What an amazing program at this year's #wclc2019 @IASLC #lcsm
Brendon Stiles @BrendonStilesMD
Almost time to wind the chat down. This has been an incredible discussion. #lcsm
Narjust Duma, M.D. @NarjustDumaMD
@drcoronacruz @lcsmchat Esto me preocupa para nuestros paises. Espero que todos los pacientes tengan acceso no solamente a los estudios moleculares pero a los medicamentos. I am worried about our countries, hope patients get access to the drugs as well. @BrendonStilesMD #LCSM
Dave Bjork @bjork5
I agree #LCSM @J2Novack @1111linno 🙌
Sue McCullough @SueMcCu30398663
Sue Mc, I am here, just watching 💚#LCSM
Brendon Stiles @BrendonStilesMD
Please share your closing thoughts! #lcsm
Matthew Katz, MD @subatomicdoc
RT @lgreco_ny: Different topic, but I'd love to see greatest hits for #astro19 relating to lc/ brain mets #lcsm @HenningWillers @BrendonSt
Brendon Stiles @BrendonStilesMD
Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. I had the pleasure of speaking with STARS PRAs and learned a lot about how they view scientific presentations: S…
Brendon Stiles @BrendonStilesMD
@SueMcCu30398663 Hi Sue! #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm
#LCSM Chat @lcsmchat
RT @NarjustDumaMD: @drcoronacruz @lcsmchat Esto me preocupa para nuestros paises. Espero que todos los pacientes tengan acceso no solamente…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. And they had some incredible mentors: @JillHW, @jillfeldman4, @jFreemanDaily, @ProjectBreath, and @dustywater.…
Jose F. Corona-Cruz @drcoronacruz
RT @NarjustDumaMD: @BrendonStilesMD A2: Testing. Testing. Testing. Particularly for our women, never smokers and young patients. #LCSM
Timothy Craig Allen @TimAllenMDJD
Thank you, @BrendonStilesMD, for hosting this great #lcsm session. It was a privilege to participate.
Laura Greco @lgreco_ny
Are you ever home? #lcsm
Brendon Stiles @BrendonStilesMD
#WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm https://t.co/kjR3NAeD7x
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Please share your closing thoughts! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm
Lung Cancer Research Foundation @lcrf_org
Great discussion on tonight's #lcsm chat. Thank you @BrendonStilesMD and @JFreemanDaily!
Jean Parks @geekbabe
RT @NarjustDumaMD: @BrendonStilesMD @lcsmchat A4: KRAS drugs are promising. It will open many doors for many of our patients. As always, we…
Timothy Craig Allen @TimAllenMDJD
RT @lcrf_org: Great discussion on tonight's #lcsm chat. Thank you @BrendonStilesMD and @JFreemanDaily!
IASLC @IASLC
The registration deadline for the IASLC 2019 North America Conference on Lung Cancer has been extended to September 25! Register now to learn about the latest developments in #LungCancer prevention, detection and care at #NACLC19 --> https://t.co/1b4iyU3MSw #LCSM https://t.co/HsSRzyXSkO
Gina Hollenbeck @GinaHollenbeck
@BrendonStilesMD The Stars program is an awesome and important addition to #WCLC. It’s a wonderful idea. I look forward to seeing how the stars use the information learned in Barcelona #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb…
Bob Steele @steele_bob
RT @lcrf_org: Great discussion on tonight's #lcsm chat. Thank you @BrendonStilesMD and @JFreemanDaily!
Betsy @wildwestannie
Tomorrow marks the 21st anniversary of my Mom’s death from lung cancer. Treatment options and current research now weren’t even dreams then! Imagine where we’ll be in another 21 years! ❤️ #lcsm
Elad Sharon @EladSharonMD
RT @StephenVLiu: T3: Some of my favorite #WCLC19 presentations on IO were the long term follow up studies. 5y follow up from the second lin…
Janet Freeman-Daily @JFreemanDaily
@DrewMoghanaki Talk to me or @KAdvocate_LCAM! #LCSM
Brendon Stiles @BrendonStilesMD
Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's support it as a community! #lcsm
#LCSM Chat @lcsmchat
Thanks to our moderator @BrendonStilesMD for tonight’s chat! #LCSM
Tim Kruser @TimothyKruserMD
Final thought relates to T5. STARS progam--amazing. We need to get some of these superstars at #ASTRO20. Can you say Miami?! #lcsm
Jean Parks @geekbabe
RT @BrendonStilesMD: #WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm htt…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's s…
Timothy Craig Allen @TimAllenMDJD
RT @lcsmchat: Thanks to our moderator @BrendonStilesMD for tonight’s chat! #LCSM
#LCSM Chat @lcsmchat
RT @IASLC: The registration deadline for the IASLC 2019 North America Conference on Lung Cancer has been extended to September 25! Register…
Gina @EAustin1969
The advances in both early detection and treatment options and spans is so amazing. We definitely have to badger, bother and pester to get more funding for more research so that many can live with this disease and not die #lcsm
Jose F. Corona-Cruz @drcoronacruz
A4. Using them in early stage preoperatively is a great opportunity to check the surgical specimens and try to understand resistance mechanisms #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @NarjustDumaMD: @BrendonStilesMD @lcsmchat A4: KRAS drugs are promising. It will open many doors for many of our patients. As always, we…
Brendon Stiles @BrendonStilesMD
@JFreemanDaily @DrewMoghanaki @KAdvocate_LCAM I would watch this guy carefully... #lcsm
#LCSM Chat @lcsmchat
RT @GinaHollenbeck: @BrendonStilesMD The Stars program is an awesome and important addition to #WCLC. It’s a wonderful idea. I look forward…
Jill Hamer-Wilson 🇨🇦 @JillHW
#KRAS treatment AMG 510 shows some promise. More research needed. #LCSM #WCLC19 #hope #lungcancer
#LCSM Chat @lcsmchat
RT @wildwestannie: Tomorrow marks the 21st anniversary of my Mom’s death from lung cancer. Treatment options and current research now were…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Great goals for the STARS program from @iaslc. We all learn a little more, work together a little better, and rememb…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's s…
Lung Cancer Research Foundation @lcrf_org
The pace of innovation in lung cancer continues to accelerate thanks to the dedication of so many people! #lcsm
Brendon Stiles @BrendonStilesMD
@TimothyKruserMD Great point! #lcsm
#LCSM Chat @lcsmchat
RT @TimothyKruserMD: Final thought relates to T5. STARS progam--amazing. We need to get some of these superstars at #ASTRO20. Can you say M…
KC Dill @kasedill
@BrendonStilesMD As always thanks for the moderation and information. Lots of exciting news and hope from the conference. I look forward to our monthly chats. #LCSM #ResearchMatters
#LCSM Chat @lcsmchat
RT @EAustin1969: The advances in both early detection and treatment options and spans is so amazing. We definitely have to badger, bother…
#LCSM Chat @lcsmchat
RT @drcoronacruz: A4. Using them in early stage preoperatively is a great opportunity to check the surgical specimens and try to understand…
Brendon Stiles @BrendonStilesMD
Thanks to everyone for participating! #lcsm
#LCSM Chat @lcsmchat
RT @lcrf_org: The pace of innovation in lung cancer continues to accelerate thanks to the dedication of so many people! #lcsm
Dave Bjork @bjork5
Thank you @IASLC and all the amazing lung cancer patient advocates who travel near and far for our community. And @BrendonStilesMD for hosting tonight. ❤️ #lcsm #community #gratitude
KC Dill @kasedill
RT @lcrf_org: The pace of innovation in lung cancer continues to accelerate thanks to the dedication of so many people! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @GinaHollenbeck: @BrendonStilesMD There was a new assay test for ROS1 developed by Ventana. Relatively cheap and you get the results in…
Narjust Duma, M.D. @NarjustDumaMD
@BrendonStilesMD @lcsmchat @IASLC Thank you, @BrendonStilesMD for moderating. @IASLC for their support and mission. And thanks to all our patients for allowing us to be part of their journey. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T5 So sorry...talking one of my college kids off the ledge. Will have to catch up later, but STARS was amazing thanks to…
Jose F. Corona-Cruz @drcoronacruz
La investigación salva muchas vidas, necesitamos más investigadores y todos los recursos posibles #LCSM
Henning Willers, MD @HenningWillers
Glad to have attended this chat. As always. Thanks & see you at #NACLC19 #LCSM
Drew Moghanaki @DrewMoghanaki
@BrendonStilesMD @JFreemanDaily @KAdvocate_LCAM Thanks Janet. #lcsm
#LCSM Chat @lcsmchat
RT @NarjustDumaMD: @BrendonStilesMD @lcsmchat @IASLC Thank you, @BrendonStilesMD for moderating. @IASLC for their support and mission.…
Laura Greco @lgreco_ny
@HenningWillers @BrendonStilesMD @lcrf_org Anything else re treatment of oligoprogressive disease? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @NarjustDumaMD: @drcoronacruz @lcsmchat Esto me preocupa para nuestros paises. Espero que todos los pacientes tengan acceso no solamente…
Brendon Stiles @BrendonStilesMD
@lcrf_org Great point. And the rapid pace is hard to keep up with. Thanks #lcsm and @lcsmchat for helping to keep patients, advocates, physicians, and researchers abreast. #lcsm
Drew Moghanaki @DrewMoghanaki
@BrendonStilesMD I will. I will. #FOMO #lcsm @jillfeldman4
Brendon Stiles @BrendonStilesMD
@HenningWillers Awesome! I will be there and am counting on meeting you! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to @IASLC for all they do for lung cancer. #lcsm
Narjust Duma, M.D. @NarjustDumaMD
@GinaHollenbeck @lcsmchat @BrendonStilesMD One of the best initiatives I have seen. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: #WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm htt…
KC Dill @kasedill
RT @NarjustDumaMD: @BrendonStilesMD @lcsmchat @IASLC Thank you, @BrendonStilesMD for moderating. @IASLC for their support and mission.…
Bob Steele @steele_bob
Time to start reviewing all of the INFO links from tonight's excellent monthly Lung Cancer Social Media Twitter Chat Session. Cheers! #lcsm
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: #WCLC19 was an incredible meeting. Great to get so many people together from so many different specialties. #lcsm htt…
Dave Bjork @bjork5
#RockStar #lcsm @BrendonStilesMD #research
Brendon Stiles @BrendonStilesMD
How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD I will be standing by my poster 😇 #lcsm
Betsy @wildwestannie
RT @bjork5: #RockStar #lcsm @BrendonStilesMD #research https://t.co/1Ost0ACUIC
Bob Steele @steele_bob
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Drew Moghanaki @DrewMoghanaki
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD Thanks @BrendonStilesMD and all participating docs and patients for a great wrap-up of @IASLC #WCLC19. It gets better every year! Looking forward to next year in #Singapore ! #LCSM
Lung Cancer Research Foundation @lcrf_org
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Narjust Duma, M.D. @NarjustDumaMD
Let's also share the Latin American Meeting. Juntos por la luncha contra el cancer de pulmon. See you in Mexico City! #LCSM @IASLC @lcsmchat @ChristianRolfo @ogarrieta @HwakeleeMD
Brendon Stiles @BrendonStilesMD
Thanks everyone. Love the community and love learning from all of you! Signing off but hope to see or hear from everyone soon. #lcsm
Jenni Chrysler @jenchrysler98
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @GinaHollenbeck: @BrendonStilesMD The Stars program is an awesome and important addition to #WCLC. It’s a wonderful idea. I look forward…
Tim Kruser @TimothyKruserMD
RT @BrendonStilesMD: How about a shout out retweet to @IASLC for all the great work they do! Thanks for everything! #lcsm
Jean Parks @geekbabe
Thanks to all the Oncologists, researchers & pt advocates & our gracious host! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Always a closing thought for me.... #Research moves the needle and has made all the difference in lung cancer. Let's s…
KC Dill @kasedill
Thank you